Oral Semaglutide Packaging Challenges

The rapid growth of oral GLP-1 therapies is creating new demands for pharmaceutical packaging. Unlike traditional tablets, oral semaglutide formulations are highly sensitive to moisture, making packaging performance critical for product stability and shelf life.

child resistant cap with silica gel desiccant

Products such as Rybelsus from Novo Nordisk highlight the industry’s shift toward oral peptide delivery systems. This trend is driving increasing demand for advanced moisture-protection packaging manufactured under strict pharmaceutical quality standards such as ISO 15378.

One of the biggest challenges is humidity control. Even small amounts of moisture exposure may affect:

peptide stability,

dissolution performance,

and long-term product quality.

As a result, pharmaceutical companies are increasingly adopting:

Desiccant Bottle systems,

CRC desiccant caps,

and high-barrier HDPE packaging.

The U.S. Food and Drug Administration also places growing emphasis on:

container closure integrity,

moisture barrier validation,

stability testing,

and pharmaceutical packaging compliance.

For packaging suppliers, ISO 15378 certification is becoming increasingly important to support:

pharmaceutical quality management,

risk control,

traceability,

and regulatory expectations in FDA-regulated markets.

desiccant bottle with silica gel

As oral GLP-1 and oral peptide drugs continue expanding globally, moisture-proof packaging and ISO15378-compliant manufacturing will become key factors in ensuring product safety and stability.